BLSM BlossomHill Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1839970 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets33.9%
Debt / equity—
Current ratio5.42x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2025Q32025-09-30 | 2025Q22025-06-30 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | — | — | — | — |
| R&D expense | $21.93M | $21.36M | $14.67M | $12.53M |
| SG&A expense | $3.55M | $3.31M | $2.06M | $1.57M |
| Operating income | -$25.48M | -$24.67M | -$16.73M | -$14.10M |
| Net income | -$24.01M | -$23.76M | -$15.98M | -$13.24M |
| EBITDA | -$25.36M | — | -$16.63M | — |
| EPS (basic) | -1.29 | -8.75 | -6.54 | -5.51 |
| EPS (diluted) | -1.29 | -8.75 | -6.54 | -5.51 |
| Weighted avg. shares (diluted) | 18.56M | 2.71M | 2.44M | 2.41M |
| Balance sheet | ||||
| Cash & equivalents | $224.90M | $95.38M | $67.81M | $79.11M |
| Current assets | — | $100.97M | — | — |
| PP&E, net | — | $1.49M | — | — |
| Total assets | — | $124.13M | — | — |
| Current liabilities | — | $18.62M | — | — |
| Total liabilities | — | $42.09M | — | — |
| Shareholders' equity | $211.08M | -$174.78M | -$111.43M | -$96.03M |
| Shares outstanding | — | 2.55M | — | — |
| Cash flow statement | ||||
| Operating cash flow | -$22.19M | — | -$11.58M | — |
| Capital expenditure | $0 | — | $22,000 | — |
| Free cash flow | -$22.19M | — | -$11.60M | — |
| Investing cash flow | $0 | — | -$22,000 | — |
| Financing cash flow | $151.72M | — | $302,000 | — |
| Depreciation & amortization | $123,000 | — | $97,000 | — |
| Stock-based compensation | $1.19M | — | $276,000 | — |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.